

เอกสารอ้างอิง

1. Executive Summary of The Third Report of The National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, And Treatment of High Blood Cholesterol In Adults (Adult Treatment Panel III). JAMA 2001;285:2486-97.
2. National Institute for Health and Clinical Excellence. NICE public health guidance 25: Prevention of cardiovascular disease at population level. In: Service NH, ed. London; 2010.
3. สุรจิต สุนทรธรรม. แนวทางเวชปฏิบัติอิงหลักฐานการตรวจและการสร้างเสริมสุขภาพในประเทศไทย. 2 ed. กรุงเทพฯ: หมอชาวบ้าน; 2001.
4. แพทยสภา, สำนักโรคไม่ติดต่อ กรมควบคุมโรค กระทรวงสาธารณสุข, คณะกรรมการการสาธารณสุข วุฒิสภา, et al. แนวทางเวชปฏิบัติสำหรับการป้องกันโรคหลอดเลือดแดงชั้นปฐมภูมิ; 2007.
5. Kaunitz H, Dayrit CS. Coconut Oil Consumption and Coronary Heart Disease. Phil J Internal Med 1992;30:165-71.
6. ณรงค์ โจนเจลา. น้ำมันมะพร้าว บทบาทต่อสุขภาพและความงาม. กรุงเทพฯ: องค์การเภสัชกรรม; 2550.
7. Sritara P, Cheepudomwit S, Chapman N, et al. Twelve-year changes in vascular risk factors and their associations with mortality in a cohort of 3499 Thais: the Electricity Generating Authority of Thailand Study. Int J Epidemiol 2003;32:461-8.
8. บรรจบ ชุณหสวัสติกุล, ณรงค์ โจนเจลา. น้ำมันมะพร้าวรักษาโรค. กรุงเทพมหานคร: บริษัท รวมทรัพย์ จำกัด; 2008.
9. บรรจบ ชุณหสวัสติกุล. น้ำมันมะพร้าว ลดโรคหัวใจ-ข้อมูลใหม่. มติชนสุดสัปดาห์ 2550 21 กันยายน พ.ศ. 2550:93-4.
10. บรรจบ ชุณหสวัสติกุล. พลิกความเชื่อเรื่องน้ำมันมะพร้าว กับคอเลสเตอรอล. มติชนสุดสัปดาห์ 2550 14 กันยายน พ.ศ. 2550:93-4.
11. ณรงค์ โจนเจลา. มหัศจรรย์น้ำมันมะพร้าว. กรุงเทพมหานคร: ชมรมอนุรักษ์และพัฒนา น้ำมันมะพร้าวแห่งประเทศไทย; 2008.
12. ณรงค์ โจนเจลา. การบรรยายประชุมวิชาการ เรื่อง บทบาทของน้ำมันมะพร้าวต่อสุขภาพและความงาม. 2547. Accessed at http://www.watpo.com/coconutoil_report.pdf on 10 มีนาคม 2554.
13. Hashim SA, Clancy RE, Hegsted DM, Stare FJ. Effect of mixed fat formula feeding on serum cholesterol level in man. Am J Clin Nutr 1959;7:30-4.

14. Davis CB, Jr., Clancy RE, Cooney BE, Hegsted DM, Hall JH. Effect of mixed fat formula feeding on serum cholesterol level in man. II. Further study utilizing a twenty per cent fat formula. *Am J Clin Nutr* 1960;8:808-11.
15. Prior IA, Davidson F, Salmond CE, Czochanska Z. Cholesterol, coconuts, and diet on Polynesian atolls: a natural experiment: the Pukapuka and Tokelau island studies. *Am J Clin Nutr* 1981;34:1552-61.
16. Mendis S, Kumarasunderam R. The effect of daily consumption of coconut fat and soya-bean fat on plasma lipids and lipoproteins of young normolipidaemic men. *Br J Nutr* 1990;63:547-52.
17. Ng TK, Hassan K, Lim JB, Lye MS, Ishak R. Nonhypercholesterolemic effects of a palm-oil diet in Malaysian volunteers. *Am J Clin Nutr* 1991;53:1015S-20S.
18. Cox C, Mann J, Sutherland W, Chisholm A, Skeaff M. Effects of coconut oil, butter, and safflower oil on lipids and lipoproteins in persons with moderately elevated cholesterol levels. *J Lipid Res* 1995;36:1787-95.
19. Cox C, Sutherland W, Mann J, de Jong S, Chisholm A, Skeaff M. Effects of dietary coconut oil, butter and safflower oil on plasma lipids, lipoproteins and lathosterol levels. *Eur J Clin Nutr* 1998;52:650-4.
20. Assuncao ML, Ferreira HS, dos Santos AF, Cabral CR, Jr., Florencio TM. Effects of dietary coconut oil on the biochemical and anthropometric profiles of women presenting abdominal obesity. *Lipids* 2009;44:593-601. Epub 2009 May 13.
21. Enig MG. A new look at coconut oil. Health and nutritional benefits from coconut oil: An important functional food for the 21th Century. In: AVOC Lauric Oils Symposium; 1996 25 April; Ho Chi Min City, Vietnam; 1996.
22. Felton CV, Crook D, Davies MJ, Oliver MF. Dietary polyunsaturated fatty acids and composition of human aortic plaques. *Lancet* 1994;344:1195-6.
23. Mozaffarian D, Rimm EB, Herrington DM. Dietary fats, carbohydrate, and progression of coronary atherosclerosis in postmenopausal women. *Am J Clin Nutr* 2004;80:1175-84.
24. Enig MG. Coconut: In support of Good Health in the 21th century. In: 36th Meeting of APCC; 1999 21 - 25 June; Phuket, Thailand.; 1999.
25. Ghosh S, Bhattacharyya DK. Medium-chain fatty acid-rich glycerides by chemical and lipase-catalyzed polyester-monoester interchange reaction. *J Am Oil Chem Soc* 1997;74:593-5.
26. Calabrese C, Myer S, Munson S, Turet P, Birdsall TC. A cross-over study of the effect of a single oral feeding of medium chain triglyceride oil vs. canola oil on post-ingestion plasma triglyceride levels in healthy men. *Altern Med Rev* 1999;4:23-8.
27. Dayrit CS. Coconut oil: Atherogenic or not? *Phil J Cardiol* 2003;31:97-104.
28. Nevin KG, Rajamohan T. Beneficial effects of virgin coconut oil on lipid parameters and in vitro LDL oxidation. *Clin Biochem* 2004;37:830-5.

29. Nevin KG, Rajamohan T. Virgin coconut oil supplemented diet increases the antioxidant status in rats. *Food Chem* 2006;99:260-66.
30. Nevin KG, Rajamohan T. Influence of virgin coconut oil on blood coagulation factors, lipid levels and LDL oxidation in cholesterol fed Sprague-Dawley rats. *the European e-Journal of Clinical Nutrition and Metabolism* 2008;3:e1-8.
31. Espinosa-Larranaga F, Vejar-Jalaf M, Medina-Santillan R. The importance of low serum levels of high-density lipoprotein cholesterol (HDL-C) as a cardiovascular risk factor. *Diab Vasc Dis Res* 2005;2 Suppl 1:S1-8.
32. Bruckert E, Hansel B. HDL-c is a powerful lipid predictor of cardiovascular diseases. *Int J Clin Pract* 2007;61:1905-13.
33. Laitinen DL, Manthena S, Webb S. Association between HDL-C concentration and risk for a major cardiovascular event. *Curr Med Res Opin* 2010;26:933-41.
34. Senn S. *Cross-over Trials in Clinical Research*. Second ed. Chichester, West Sussex. : John Wiley & Sons, Ltd; 2002.
35. St-Onge MP, Jones PJ. Physiological effects of medium-chain triglycerides: potential agents in the prevention of obesity. *J Nutr* 2002;132:329-32.
36. Scalfi L, Coltorti A, Contaldo F. Postprandial thermogenesis in lean and obese subjects after meals supplemented with medium-chain and long-chain triglycerides. *Am J Clin Nutr* 1991;53:1130-3.
37. Van Wymelbeke V, Himaya A, Louis-Sylvestre J, Fantino M. Influence of medium-chain and long-chain triacylglycerols on the control of food intake in men. *Am J Clin Nutr* 1998;68:226-34.
38. Reiser R, Probstfield JL, Silvers A, et al. Plasma lipid and lipoprotein response of humans to beef fat, coconut oil and safflower oil. *Am J Clin Nutr* 1985;42:190-7.
39. Stein O, Stein Y. Lipid transfer proteins (LTP) and atherosclerosis. *Atherosclerosis* 2005;178:217-30.
40. Green SR, Pittman RC. Comparative acyl specificities for transfer and selective uptake of high density lipoprotein cholesteryl esters. *J Lipid Res* 1991;32:457-67.
41. Le Goff W, Guerin M, Chapman MJ. Pharmacological modulation of cholesteryl ester transfer protein, a new therapeutic target in atherogenic dyslipidemia. *Pharmacol Ther* 2004;101:17-38.
42. van der Steeg WA, Kuivenhoven JA, Klerkx AH, Boekholdt SM, Hovingh GK, Kastelein JJ. Role of CETP inhibitors in the treatment of dyslipidemia. *Curr Opin Lipidol* 2004;15:631-6.
43. Brewer HB, Jr. Increasing HDL Cholesterol Levels. *N Engl J Med* 2004;350:1491-4.
44. Brousseau ME, Schaefer EJ, Wolfe ML, et al. Effects of an inhibitor of cholesteryl ester transfer protein on HDL cholesterol. *N Engl J Med* 2004;350:1505-15.
45. Robinson JG. Dalcetrapib: a review of Phase II data. *Expert Opin Investig Drugs* 2010;19:795-805.

46. Bloomfield D, Carlson GL, Sapre A, et al. Efficacy and safety of the cholesteryl ester transfer protein inhibitor anacetrapib as monotherapy and coadministered with atorvastatin in dyslipidemic patients. *Am Heart J* 2009;157:352-60 e2.
47. Stein EA, Roth EM, Rhyne JM, Burgess T, Kallend D, Robinson JG. Safety and tolerability of dalcetrapib (RO4607381/JTT-705): results from a 48-week trial. *Eur Heart J* 2010;31:480-8.
48. Sacks FM. The role of high-density lipoprotein (HDL) cholesterol in the prevention and treatment of coronary heart disease: expert group recommendations. *Am J Cardiol* 2002;90:139-43.
49. Gotto AM, Jr., Brinton EA. Assessing low levels of high-density lipoprotein cholesterol as a risk factor in coronary heart disease: a working group report and update. *J Am Coll Cardiol* 2004;43:717-24.
50. สำนักงานสำรวจสุขภาพประชาชนไทย. รายงานการสำรวจสุขภาพประชาชนไทย โดยการตรวจร่างกาย ครั้งที่ 4 พ.ศ. 2551-2.
51. Lohsoonthorn V, Lertmaharit S, Williams MA. Prevalence of metabolic syndrome among professional and office workers in Bangkok, Thailand. *J Med Assoc Thai* 2007;90:1908-15.
52. Selvin E, Marinopoulos S, Berkenblit G, et al. Meta-analysis: glycosylated hemoglobin and cardiovascular disease in diabetes mellitus. *Ann Intern Med* 2004;141:421-31.
53. Chuengsamarn S, Rattanamongkoulgul S. Metabolic syndrome and atherosclerotic risk factors as determinants of blood sugar control in diabetic patients: a retrospective cohort study. *J Med Assoc Thai* 2010;93:177-82.
54. Worawongprapa O. Glycemic control in diabetes with metabolic syndrome in community hospital. *J Med Assoc Thai* 2008;91:641-7.